"RedHill Biopharma launches trial of combination therapy for prostate cancer" was originally created and published by ...

The six biggest myths about prostate cancer – as it is named England’s most common cancer - There has been a 25 per cent ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

I was in a conversation with an elderly male relative recently and was shocked at the number of people we all know, some of them having been in government at the highest level, who succumbed to ...

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

Prostate cancer is often seen as an unavoidable part of ageing, especially among men, but there are many myths that can create confusion.

Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer Cases Jan. 3, 2025 — A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer ...

The new urine test looks at 18 genes that are linked to high-risk prostate cancer. Previous research showed that MPS2 could ...

The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.